GlassScriptPhysician profile
Jordan L Engelman
NPI 1578988739
$2,797.56
in general payments reported to CMS, 2019-2025
35 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $720 · 2023: $543 · 2024: $328 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.82 | 2021-2024 | |
| Lilly USA, LLC | $340.19 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $301.66 | 2021-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.40 | 2021-2025 | Jardiance |
| Amgen INC. | $108.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $99.23 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $86.17 | 2025 | |
| Noven Therapeutics, LLC | $85.32 | 2023-2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $82.21 | 2021-2023 | Belsomra, Steglujan, Steglatro |
| Janssen Pharmaceuticals, INC | $65.85 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.20 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $51.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $51.09 | 2021-2024 | |
| Dexcom, INC. | $48.80 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $47.42 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $43.47 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $43.30 | 2023-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $40.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.71 | 2022 | |
| Eisai INC. | $35.94 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.25 | 2021-2023 | |
| Boston Scientific Corporation | $27.32 | 2021 | |
| Biogen, INC. | $22.55 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.23 | 2021 | |
| Esperion Therapeutics, INC. | $20.11 | 2021 | |
| Astellas Pharma US INC | $18.97 | 2023 | Myrbetriq |
| Clarus Therapeutics INC. | $17.48 | 2021 | |
| Genentech USA, INC. | $16.62 | 2021 | |
| Antares Pharma, INC. | $16.40 | 2025 | Xyosted |
| Misonix INC | $15.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2022 | |
| Exeltis, USA INC. | $15.01 | 2023 | Slynd |
| Arbor Pharmaceuticals, INC. | $13.79 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.52 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Engelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.